cancers Review Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives Sara Fancelli 1 , Enrico Caliman 1,2 , Francesca Mazzoni 1, Marco Brugia 1, Francesca Castiglione 3, Luca Voltolini 2,4, Serena Pillozzi 1 and Lorenzo Antonuzzo 1,2,* 1 Medical Oncology Unit, Careggi University Hospital, 50134 Florence, Italy; sara.fancelli@unifi.it (S.F.); enrico.caliman@unifi.it (E.C.);
[email protected] (F.M.);
[email protected] (M.B.); serena.pillozzi@unifi.it (S.P.) 2 Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy; luca.voltolini@unifi.it 3 Pathological Histology and Molecular Diagnostics Unit, Careggi University Hospital, 50134 Florence, Italy;
[email protected] 4 Thoraco-Pulmonary Surgery Unit, Careggi University Hospital, 50134 Florence, Italy * Correspondence: lorenzo.antonuzzo@unifi.it; Tel.: +39-055-7948406 Simple Summary: REarranged during Transfection (RET) is an emerging target for several types of cancer, including non-small cell lung cancer (NSCLC). The recent U.S. FDA approval of pralsetinib and selpercatinib raises issues regarding the emergence of secondary mutations and amplifications involved in parallel signaling pathways and receptors, liable for resistance mechanisms. The aim of this review is to explore recent knowledge on RET resistance in NSCLC in pre-clinic and in clinical Citation: Fancelli, S.; Caliman, E.; settings and accordingly, the state-of-the-art in new drugs or combination of drugs development. Mazzoni, F.; Brugia, M.; Castiglione, F.; Voltolini, L.; Pillozzi, S.; Antonuzzo, L. Chasing the Target: New Phenomena Abstract: The potent, RET-selective tyrosine kinase inhibitors (TKIs) pralsetinib and selpercatinib, of Resistance to Novel Selective RET are effective against the RET V804L/M gatekeeper mutants, however, adaptive mutations that cause Inhibitors in Lung Cancer.